Business
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system, today announced financial results for its fiscal third quarter ended March 31, 2026, and provided a business update.
About this update from Palatin Technologies, Inc.
[{"type":"text","content":"Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 ","length":180,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome","length":147,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Once-weekly injectable MC4R selective peptide agonist remains on track for an IND submission in the fourth quarter of calendar 2026","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":131,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Oral MC4R selective agonist program is advancing, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027","length":150,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":150,"olType":false}]},{"val":[{"type":"text","content":"Focus is on developing best-in-class MC4R candidates designed to enhance potency, improve tolerability, reduce off-target effects, including those associated with hyperpigmentation, and support safe and effective long-term use","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call and webcast scheduled for May 13, 2026, at 11:00 a.m. ET","length":72,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":726,"olType":false},{"type":"text","content":"PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system, today announced financial results for its fiscal third quarter ended March 31, 2026, and provided a business update.","length":312,"tagName":"p"},{"type":"image","alt":"Palatin Technologies, Inc.","displaySize":"","headline":null,"caption":"Palatin Technologies, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":345,"url":"https://media.zenfs.com/en/prnewswire.com/965a03f88317259fbf5e1a6eed8134bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AQfwD723Z4IUxlX8GukUvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYwODtjZj13ZWJw/https://media.zenfs.com/en/prnewswi...